肺肿瘤立体定向消融放疗后肺功能取决于受照肺区域通气功能
该回顾性研究纳入27例接受肺肿瘤立体定向消融放疗(SABR)的患者,基于4-D CT定义通气比值VR20BED3(20Gy生物等效剂量等剂量体积内平均通气与全肺平均通气之比)。结果发现VR20BED3较高者FEV1下降更明显,而VR20BED3较低者FEV1改善,提示受照区域通气功能影响SABR后全局肺功能变化。
要点
- VR20BED3较高(受照区域通气好)者SABR后FEV1下降更明显。
- VR20BED3较低(受照区域通气差)者SABR后FEV1有所改善。
- VR20BED3与SABR后PFT时间共同预测FEV1变化(R2=0.25,p=0.03)。
核心结论
- SABR照射高通气功能肺区域后全局肺功能变差,照射低通气功能区域后全局肺功能改善。
- VR20BED3若在更大研究中验证为SABR后PFT的预测因子,可用于个体化治疗计划以保留甚至改善肺功能。
研究设计与样本
- 回顾性研究纳入2007至2014年在本机构接受SABR的27例患者,均无既往胸部放疗、有治疗前4-D CT且SABR前后PFT间隔<15个月。
- VR20BED3定义为20Gy生物等效剂量(α/β=3Gy)等剂量体积内平均通气与全肺平均通气之比,通气基于形变配准的4-D CT吸气/呼气相逐体素体积变化的Jacobian计算。
主要发现
- 多数患者按GOLD标准为中度至极重度COPD(n=19,70.1%)。
- VR20BED3较高显著预测FEV1较基线下降更差(ΔFEV1/FEV1pre,p=0.04)。
- VR20BED3>1(高区域通气)者n=7,ΔFEV1/FEV1pre中位数=-0.16(范围-0.230至-0.20)。
- VR20BED3<1(低区域通气)者n=5,ΔFEV1/FEV1pre中位数=0.13(范围0.07至0.20)。
- 多变量线性模型中VR20BED3增加和SABR后PFT时间延长预测ΔFEV1/FEV1pre下降(R2=0.25,p=0.03)。
临床怎么用
- 治疗计划时可参考VR20BED3评估受照肺区域通气功能,以预判SABR后全局肺功能变化方向。
- 对高通气功能区域照射可能需权衡肺功能下降风险,低通气区域照射可能不影响甚至改善肺功能。
局限性
- 回顾性研究,样本量仅27例。
- VR20BED3作为SABR后PFT预测因子尚需更大研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine if regional ventilation within irradiated lung volume predicts change in pulmonary function test (PFT) measurements after stereotactic ablative radiotherapy (SABR) of lung tumors. METHODS: We retrospectively identified 27 patients treated from 2007 to 2014 at our institution who received: (1) SABR without prior thoracic radiation; (2) pre-treatment 4-dimensional computed tomography (4-D CT) imaging; (3) pre- and post-SABR PFTs <15months from treatment. We defined the ventilation ratio (VR20BED3) as the quotient of mean ventilation (mean Jacobian-based per-voxel volume change on deformably registered inhale/exhale 4-D CT phases) within the 20Gy biologically effective dose (α/β=3Gy) isodose volume and that of the total lung volume (TLV). RESULTS: Most patients had moderate to very severe COPD by GOLD criteria (n=19, 70.1%). Higher VR20BED3 significantly predicted worse change in Forced Expiratory Volume/s normalized by baseline value (ΔFEV1/FEV1pre, p=0.04); n=7 had VR20BED3>1 (high regional ventilation) and worse ΔFEV1/FEV1pre (median=-0.16, range=-0.230 to -0.20). Five had VR20BED3<1 (low regional ventilation) and improved ΔFEV1/FEV1pre (median=0.13, range=0.07 to 0.20). In a multivariable linear model, increasing VR20BED3 and time to post-SABR PFT predicted decreasing ΔFEV1/FEV1pre (R2=0.25, p=0.03). CONCLUSIONS: After SABR to high versus low functioning lung regions, we found worsened or improved global pulmonary function, respectively. If pre-SABR VR20BED3 is validated as a predictor of eventual post-SABR PFT in larger studies, it may be used for individualized treatment planning to preserve or even improve pulmonary function after SABR.
引用
- Binkley MS, King MT, Shrager JB, et al. Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung. Radiother Oncol. 2017. PMID: 28460826. doi:10.1016/j.radonc.2017.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。